Cyanosis other imaging findings

Cyanosis Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cyanosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cyanosis other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cyanosis other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cyanosis other imaging findings
CDC on Cyanosis other imaging findings
Cyanosis other imaging findings in the news
Blogs on Cyanosis other imaging findings
Directions to Hospitals Treating Cyanosis
Risk calculators and risk factors for Cyanosis other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2] Amandeep Singh M.D.[3]

Overview

Cardiac catheterization is an invasive study for the anatomic and physiological assessment of patients with cyanotic congenital heart disease

Cardiac catheterization

Cardiac catheterization is the gold standard for the anatomic and physiological assessment of patients with cyanotic congenital heart disease when determining of the anatomy of congenital heart disease is inadequate by noninvasive imaging.

Cardiac Catheterization

Recommendations for catheterization in congenital heart disease

(Class I, Level of Evidence A):

❑ Obtaining hemodynamic and anatomic data at the time of intervention

(Class I, Level of Evidence B) :

❑ Assessment of pulmonary resistance and reversibility of pulmonary hypertension in patients with CHD or primary pulmonary hypertension for surgical procedure or medical decisions ❑ Assessment of complex pulmonary atresia for determination of lung segmental pulmonary vascular supply, especially when noninvasive imaging are inadequate ❑ Determination of coronary circulation in pulmonary atresia with intact septum ❑ Follow-up of graft vasculopathy after cardiac transplantation

(Class I , Level of Evidence C)

❑ Assessment of patient before cardiac transplantation

(Class 2a, Level of Evidence B)

❑ Determination of pulmonary pressure/resistance and transpulmonary gradient in palliated single-ventricle patients before a staged Fontan procedure ❑ Assessment of cardiomyopathy or myocarditis ❑ Assessment of suspected congenital coronary artery anomalies

(Class 2a, Level of Evidence C)

❑ In any CHD patient in whom complete diagnosis and information cannot be obtained by noninvasive testing ❑ Assessment of anatomy and hemodynamics in postoperative cardiac patients when the early postoperative course is unexpectedly complicated and noninvasive imaging techniques ( cardiac MRA, cardiac CT angiography) fail to diagnose